MenB survivors call for Bexsero coverage in Australia

Australian survivors of the deadly meningococcal B strain are mounting pressure on the country's Pharmaceutical Benefits Advisory Committee to include Novartis' ($NVS) Bexsero, the only approved vaccine for the disease, on its national immunization plan when it meets next month. The committee has already rejected the jab once, dismissing the Swiss pharma's application last November on grounds that it wasn't worth the cost. But its counterpart in the U.K., for one, has already done an about-face on the vaccine: After leaving it off its national program, the country's Joint Committee on Vaccination and Immunisation in March OK'd Bexsero for all babies on the condition that Novartis negotiate a "cost-effective price." Story | More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

Find out how PDA can help you succeed with custom solutions and training for your employees – at your facility, our facility, or virtually.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.